FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.13  |  FHIR Version n/a  User: [n/a]

17075511000001108: Revolade 25mg tablets (GlaxoSmithKline UK Ltd) (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 02-Jun 2010. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
59537101000001114 Revolade 25mg tablets (GlaxoSmithKline UK Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
92707101000001112 Revolade 25mg tablets (Novartis Pharmaceuticals UK Ltd) en Synonym Active Only initial character case insensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) Is a Product containing precisely eltrombopag (as eltrombopag olamine) 25 milligram/1 each conventional release oral tablet (clinical drug) true Inferred relationship Existential restriction modifier
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) Is a Product containing precisely eltrombopag 25 milligram/1 each conventional release oral tablet false Inferred relationship Existential restriction modifier
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) Has active ingredient Eltrombopag false Inferred relationship Existential restriction modifier
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) Has manufactured dose form Conventional release oral tablet true Inferred relationship Existential restriction modifier
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) Has excipient Polysorbate false Inferred relationship Existential restriction modifier
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) Is a Revolade true Inferred relationship Existential restriction modifier
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) Is a Actual medicinal product true Inferred relationship Existential restriction modifier
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) Has specific active ingredient Eltrombopag olamine true Inferred relationship Existential restriction modifier
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) Has NHS dm+d (dictionary of medicines and devices) basis of strength substance Eltrombopag true Inferred relationship Existential restriction modifier
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) Has dispensed dose form Tablet true Inferred relationship Existential restriction modifier
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) Has basis of strength substance Eltrombopag true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Revolade 25mg tablets (GlaxoSmithKline UK Ltd) 28 tablet 4 x 7 tablets Has AMP True Revolade 25mg tablets (GlaxoSmithKline UK Ltd) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start